As weight-loss drug orders surge, global funds pile into China’s WuXi AppTec
Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Receives a Buy from Citi
China's 1H25 Innovative Drug Out-Licensing Deal Value Exceeds USD100 Billion, Hitting New High
WuXi AppTec joins FTSE4Good Index Series for fourth straight year
Chinese biotech overtakes AI as emerging-market growth trade
China's Humanoid Robot Products Exceed 400 Models, Accounting for Over Half of Global Total